锦欣生殖(01951)发布公告，于2025年12月5日斥资1979.8万港元回购772.2万股。 ...

格隆汇12月5日丨锦欣生殖(01951.HK)公告，12月5日耗资1979.8万港元回购772.2万股，回购价格每股 2.55-2.58港元。 ...

FF305 | | | 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 錦欣生殖醫療集團有限公司 呈交日期： 2025年12月5日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01951 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | 已發行股份總數 | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容 所產生或因依賴該等內容而引致的任何損失承擔任何責任。 Jinxin Fertility Group Limited * 1951 2025年12月5日舉行的股東特別大會投票結果 茲提述錦欣生殖醫療集團有限公司*（「本公司」）日期為2025年11月19日的通函（「該通 函」），當中載列（其中包括）本公司股東特別大會（「股東特別大會」）通告（「該通告」）。除 文義另有所指外，本公告所用詞彙與該通函所界定者具有相同涵義。 於2025年12月5日舉行的股東特別大會上，該通告所載的所有提呈決議案以投票方式表 決。 全體董事親身或以電子方式出席股東特別大會。 於股東特別大會上，本公司的香港證券登記處香港中央證券登記有限公司獲委任為監票 人負責點票事宜。於股東特別大會上提呈的各項決議案的投票結果如下： - 1 - | | | 所投票數及佔投票總數之 概約百分比 | | | --- | --- | --- | --- | | | 普通決議案 | | | | | | 贊成 ...

12月1日晚间，锦欣生殖(01951)发布一则公告，宣布"拟不少于1亿港元的总价格购回股份"，认为其"股份目前的交易价格并未反映其内在价值或本公司的实 际业务前景"。 智通财经APP观察到，自今年7月29日盘中触及阶段性股价高点，锦欣生殖股价一路波动下跌，11月24日盘中股价一度跌至2.33港元，刷新年内新低。而拉 长时间线看，今年也是其股价连续下跌的第五年，按2021年高点23.79港元计算，锦欣生殖股价已跌去9成。因此，锦欣生殖选择在此节点宣布回购，显然是 希望能够提振市场信心。 港股通抄底押注，回购带来"赚钱信号"? 正如上文提到，自7月29日触及阶段性高点以来，锦欣生殖股价便一直处在波动下行通道中。具体来看，7月29日大幅越过BOLL线上轨拉出一根大阴线后， 锦欣生殖在20天内走出一个"深V走势"，股价快速下探至下轨附近，再在5个交易日内累涨超15%将股价重新拉回上轨，但8月18日的一根长上影线也预示着 多方力量的枯竭。 8月19日，锦欣生殖开启了一段近乎13连阴的快速下行行情。在此过程中，BOLL线开口向下打开引导股价快速下跌。结合量能来看，此阶段锦欣生殖的每 日成交量持续萎缩，预示着场外持币者处于 ...

12月1日晚间，锦欣生殖(01951)发布一则公告，宣布"拟不少于1亿港元的总价格购回股份"，认为其"股份目前的交易价格并未反映其内在价值或本公司的实 际业务前景"。 智通财经APP观察到，自今年7月29日盘中触及阶段性股价高点，锦欣生殖股价一路波动下跌，11月24日盘中股价一度跌至2.33港元，刷新年内新低。而拉 长时间线看，今年也是其股价连续下跌的第五年，按2021年高点23.79港元计算，锦欣生殖股价已跌去9成。因此，锦欣生殖选择在此节点宣布回购，显然是 希望能够提振市场信心。 港股通抄底押注，回购带来"赚钱信号"? 正如上文提到，自7月29日触及阶段性高点以来，锦欣生殖股价便一直处在波动下行通道中。具体来看，7月29日大幅越过BOLL线上轨拉出一根大阴线后， 锦欣生殖在20天内走出一个"深V走势"，股价快速下探至下轨附近，再在5个交易日内累涨超15%将股价重新拉回上轨，但8月18日的一根长上影线也预示着 多方力量的枯竭。 8月19日，锦欣生殖开启了一段近乎13连阴的快速下行行情。在此过程中，BOLL线开口向下打开引导股价快速下跌。结合量能来看，此阶段锦欣生殖的每 日成交量持续萎缩，预示着场外持币者处于 ...

人民财讯12月4日电，近日，上海市科学技术委员会对《上海市生物医药"新优药械"产品目录》(第七 批)进行公示，24款"新优药械"列入目录。由复星诊疗科技旗下企业复拓知达自主研发的一次性使用肺 结节三维标识定位标记物入选。 ...

Market Overview - The Hong Kong stock market experienced fluctuations, with the Hang Seng Index closing at 23,831 points, down 145 points or 0.61% [1] - The US stock market saw declines across major indices, with the Dow Jones falling by 427.09 points or 0.90% [2] - Southbound funds maintained a net inflow of 121.9 billion HKD in November, indicating continued interest in Hong Kong stocks [3] Sector Performance - The materials sector, particularly non-ferrous metals, led the gains in the Hong Kong market, with notable increases in stock prices for companies like Sunny Optical Technology, which rose by 6.2%, and Zijin Mining, which increased by 5.3% [1][5] - In the US market, technology stocks faced profit-taking pressure, particularly in AI-related stocks, contributing to the overall market decline [2] Investment Opportunities - The report emphasizes the importance of technological self-reliance as a core theme for future performance in the Hong Kong market, suggesting that leading companies in AI, semiconductors, and industrial software may present long-term growth opportunities [3] - Specific recommendations include focusing on sectors with lower valuations and higher dividends, as well as companies benefiting from anticipated Federal Reserve interest rate cuts [3] Company Highlights - XPeng Motors reported a 19% year-on-year increase in vehicle deliveries for November, totaling 36,728 units, and a cumulative delivery of 391,937 units for the year, reflecting a 156% increase [9] - Alibaba, ZTE, and Meituan were among the top net purchases by southbound funds, indicating strong investor interest in these companies [9] Stock Performance - The Hang Seng Index and its sub-indices showed varied performance over the past month, with the Hang Seng Technology Index up by 0.8% [16] - Notable stock performances include Tencent Holdings, which saw a 1.3% increase, and Alibaba, which rose by 2.2% [16]

Core Viewpoint - Southbound funds have significantly increased their holdings in Jinxin Reproductive Medicine (01951.HK), indicating strong investor interest in the company [1] Group 1: Shareholding Changes - On December 1, southbound funds increased their holdings by 2.9025 million shares, representing a 0.20% change [2] - Over the past five trading days, there has been a cumulative net increase of 27.119 million shares held by southbound funds [1][2] - In the last 20 trading days, southbound funds have increased their holdings on 15 occasions, with a total net increase of 48.7178 million shares [1] Group 2: Current Holdings - As of now, southbound funds hold a total of 1.485 billion shares of Jinxin Reproductive Medicine, accounting for 53.83% of the company's issued ordinary shares [1][2] Group 3: Company Overview - Jinxin Reproductive Medicine is an investment holding company primarily providing in vitro fertilization (IVF) services [2] - The company offers a range of services including assisted reproductive services, management services, mobile surgical center facilities, auxiliary medical services, and sales of medical consumables and equipment, mainly in China and the United States [2]

Core Viewpoint - The company, Jinxin Reproductive Medicine (01951), has announced a share buyback program, indicating that its current trading price does not reflect its intrinsic value or actual business prospects [1] Group 1: Share Buyback Announcement - The company is authorized to repurchase up to 274 million shares, which represents 10% of the total shares issued as of the date of the annual general meeting, excluding treasury shares [1] - The board of directors has resolved to utilize the buyback authorization to repurchase shares in the open market at a total price of no less than HKD 100 million [1] - The proposed share buyback is seen as a demonstration of the company's confidence in its business development prospects [1] Group 2: Financial Position - The company believes that its existing financial resources are sufficient to support the proposed share buyback while maintaining a robust financial position [1]